Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Minerva Neurosciences (NERV) EPS (Weighted Average and Diluted) (2019 - 2026)

Minerva Neurosciences filings provide 2 years of EPS (Weighted Average and Diluted) readings, the most recent being -$3.99 for Q4 2021.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 2116.67% to -$3.99 in Q4 2021 year-over-year; TTM through Dec 2021 was -$6.14, a N/A change, with the full-year FY2025 number at -$34.67, down 18347.37% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$3.99 in Q4 2021 for Minerva Neurosciences, down from -$1.72 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.73 in Q2 2020 to a low of -$3.99 in Q4 2021.